Company News
Edgewise Therapeutics Shares Fall 25% on Trial
Edgewise Therapeutics shares dropped 25% after releasing top‑line data from its Phase 2 CIRRUS‑HCM trial of EDG‑7500.
The trial enrolled 53 HCM patients, with 90% of obstructive and 88% of non‑obstruc
